Innate Pharma SA Class A IPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €1.25
- Day Range
- €1.22–1.27
- 52-Week Range
- €1.03–2.33
- Bid/Ask
- €1.22 / €1.29
- Shares Outstanding
- 111.70M
- Market Cap
- €140.30M
- Volume/Avg
- 174,462 / 463,259
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 27.62
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 163
Valuation
Metric | IPH |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 27.62 |
Price/Cash Flow | — |
Price/Earnings
IPH
Financial Strength
Metric | IPH |
|---|---|
Quick Ratio | 0.47 |
Current Ratio | 0.60 |
Interest Coverage | −125.67 |
Quick Ratio
IPH
Profitability
Metric | IPH |
|---|---|
Return on Assets (Normalized) | −70.64% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,065.63% |
Return on Assets
IPH
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|$>Dc%q% | LOCK|H!#b | $139B | |||
| Moderna Inc MRNA | LOCK|pVyljv | LOCK|Zq | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|hz$NHH | LOCK|$lB! | $94B | |||
| argenx SE ADR ARGX | LOCK|s@mPbh | LOCK|^%D | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|M^>d^% | LOCK|f? | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|#!BzH&dY | LOCK|%#Fn? | $30B | |||
| Incyte Corp INCY | LOCK|>^#^^Y | LOCK|#X | $24B | |||
| BioNTech SE ADR BNTX | LOCK|Z?C%@%b | LOCK|jMy | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|jxX%$l# | LOCK|%FN@! | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|>mDwks | LOCK|!k& | $15B |
United States